The President and Chief Executive Officer of Rolls-Royce North America, James Guyette, was once again seen selling shares, this time following the vesting of shares awarded under the company's performance share plan.

Guyette was awarded 137,075 shares and subsequently sold 55,900 of them, earning £570,471 to cover the tax liability.

Fellow board member Mark Morris traded in 32,607 shares; 16,957 of which were sold to discharge the tax liability on 32,607 vested shares, plus a further 15,650. All were disposed of at 1,020.52p each. He earned £159,711 from the transaction.

At the end of last month the global power systems company announced that it had been awarded a $40m contract to supply equipment and related services to power the flow of natural gas through the Uzbekistan section of the Turkmenistan-China natural gas pipeline.

The FTSE 100-listed company will supply Asia Trans Gas (ATG), a joint venture between Uzbekistan's Uzbekneftegaz and China's National Petroleum Corporation, with three RB211 gas turbine driven pipeline compressor units for operation at a compressor station on the 530km Uzbekistan section of the 1,830km Turkmenistan-China natural gas pipeline.


Top Director Buys

Biotech Growth Trust (The) (BIOG)
Director name: Dr John Gordon
Amount purchased: 10,000 @ 350.25p
Value: £35,025


Top Director Sells

Rolls-Royce Holdings (RR.)
Director name: Mr Colin P Smith
Amount sold: 60,860 @ 1,020.52p
Value: £621,088

Rolls-Royce Holdings (RR.)
Director name: Mr James Guyette
Amount sold: 55,900 @ 1,020.52p
Value: c

Rolls-Royce Holdings (RR.)
Director name: Mr Mark Morris
Amount sold: 16,957 @ 1,020.52p
Value: £173,050

Rolls-Royce Holdings (RR.)
Director name: Mr Mark Morris
Amount sold: 15,650 @ 1,020.52p
Value: £159,711

Biotech Growth Trust (The) (BIOG)
Director name: Dr John Gordon
Amount sold: 10,000 @ 350.00p
Value: £35,000

Related share prices
Rolls-Royce Holdings (RR.) share price
Biotech Growth Trust (The) (BIOG) share price